- Home
- PTA vs AMPH Comparison
PTA vs AMPH Comparison
Compare PTA & AMPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- AMPH
- Stock Information
- Founded
- PTA 2020
- AMPH 1996
- Country
- PTA United States
- AMPH United States
- Employees
- PTA N/A
- AMPH N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- AMPH Biotechnology: Pharmaceutical Preparations
- Sector
- PTA Finance
- AMPH Health Care
- Exchange
- PTA Nasdaq
- AMPH Nasdaq
- Market Cap
- PTA 1.1B
- AMPH 1.1B
- IPO Year
- PTA N/A
- AMPH 2014
- Fundamental
- Price
- PTA $19.67
- AMPH $26.01
- Analyst Decision
- PTA
- AMPH Hold
- Analyst Count
- PTA 0
- AMPH 5
- Target Price
- PTA N/A
- AMPH $38.00
- AVG Volume (30 Days)
- PTA 159.2K
- AMPH 538.1K
- Earning Date
- PTA 01-01-0001
- AMPH 05-07-2025
- Dividend Yield
- PTA 8.31%
- AMPH N/A
- EPS Growth
- PTA N/A
- AMPH N/A
- EPS
- PTA N/A
- AMPH 2.77
- Revenue
- PTA N/A
- AMPH $730,659,000.00
- Revenue This Year
- PTA N/A
- AMPH $0.65
- Revenue Next Year
- PTA N/A
- AMPH $5.26
- P/E Ratio
- PTA N/A
- AMPH $9.42
- Revenue Growth
- PTA N/A
- AMPH 8.05
- 52 Week Low
- PTA $15.84
- AMPH $22.64
- 52 Week High
- PTA $19.67
- AMPH $53.96
- Technical
- Relative Strength Index (RSI)
- PTA 64.47
- AMPH 58.45
- Support Level
- PTA $19.02
- AMPH $25.15
- Resistance Level
- PTA $19.40
- AMPH $25.72
- Average True Range (ATR)
- PTA 0.23
- AMPH 0.75
- MACD
- PTA 0.03
- AMPH 0.22
- Stochastic Oscillator
- PTA 95.59
- AMPH 94.61
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About AMPH Amphastar Pharmaceuticals Inc.
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.